Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience

Dattilo, Giuseppe; Bitto, Roberto; Correale, Michele; Morabito, Claudia; Vaccaro, Vittoria; Laterra, Giulia; Casale, Matteo; Crea, Pasquale; Bella, Gianluca Di; Luzza, Francesco; Migliorato, Alba; Katsiki, Niki; Gregorio, Cesare de

doi:10.23736/s2724-5683.20.05494-8

Cited by 6 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the score of physical functioning, role physical functioning, general health, vitality, social functioning, role emotional, and mental health were significantly improved. On the whole, PCS was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the MCS was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001), which is consistent with previous studies [39,40]. Significant improvement in quality of life was strongly associated with improved cardiac function.…”

Section: Approved Galley Proofsupporting

confidence: 89%

“…The SF-36 scale is an important indicator to evaluate quality of life [38]. A study of 37 HFrEF patients confirmed that SV treatment not only significantly reduced BNP and NT-proBNP, but also significantly improved quality of life [39]. In a multicenter prospective study that enrolled 302 patients with HFrEF, ARB/ACEI was replaced by SV and patients were followed up for 1 year.…”

Section: Approved Galley Proofmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Yao,

Wang,

et al. 2024

Med Sci Monit

View full text Add to dashboard Cite

Background Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). Material/Methods From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People’s Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100–400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. Results We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). Conclusions We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.

show abstract

Section: Approved Galley Proofsupporting

confidence: 89%

Section: Approved Galley Proofmentioning

confidence: 99%

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Yao,

Wang,

et al. 2024

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…We have recently demonstrated, in real-life data and in agreement with data from international literature, that the use of S/V in patients with HFrEF, and in maximal therapy according to guidelines, leads to an improvement in the perceived quality of life, increased resistance to physical effort, and an improvement in cardiac performance [12][13][14][15][16][17][18][19]. These improvements do not occur simultaneously over time, are independent of the aetiology of HF, are independent of the dose as long as the patient takes the maximum tolerated dose, and they are the same even in patients at high arrhythmic risk and taking high doses of antiarrhythmics and ICD carriers [12][13][14][15][16][17][18][19].…”

Section: Introductionsupporting

confidence: 84%

The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population

Dattilo,

Laterra,

Licordari

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year mortality in stable patients, whereas, in recently hospitalized patients, the 1-year mortality rates exceed 20%. The Sacubitril/Valsartan (S/V), the first angiotensin receptor neprilysin inhibitor (ARNI), significantly reduced both HF hospitalization and cardiovascular mortality. Aim of the study: to evaluate the effect of S/V in a follow-up period of 5 years from the beginning of the therapy. We compared the one-year outcomes of S/V use with those obtained after 5 years of therapy, monitoring the long-term effects in a real-world population with HFrEF. Methods: Seventy consecutive patients with HFrEF and eligible for ARNI, according to PARADIGM-HF criteria, were enrolled. All patients had an overall follow-up of 60 months, during which time they underwent standard transthoracic echocardiography (TTE) with Global Longitudinal Strain (GLS) evaluation, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Six Minutes Walking Test (6MWT), and blood tests (NT-pro-BNP and BNP, renal function tests). Results: NTproBNP values were reduced significantly among the three time-points (p < 0.001). Among echocardiographic parameters, left ventricle end-diastolic volume (LV EDV) and E/e’ significantly were reduced at the first evaluation (12 months), while left ventricle end-systolic volume (LV ESV) decreased during all follow-ups (p < 0.001). LV EF (p < 0.001) and GLS (p < 0.001) significantly increased at both evaluations. The 6MWT (p < 0.001) and KCCQ scores (p < 0.001) increased significantly in the first 12 months and remained stable along the other time-points. NYHA class showed an increase in class 1 subjects and a decrease in class 3 subjects during follow-up. NTproBNP, BNP, 6MWT, and KCCQ scores showed a significant change in the first 12 months, while LVEF, GLS, and ESV changed during all evaluations. Conclusions: We verified that the improvements obtained after one year of therapy had not reached a plateau phase but continued to improve and were statistically significant at 5 years. Although our data should be confirmed in larger and multicentre studies, we can state that the utilization of Sacubitril/Valsartan has catalysed substantial transformations in the prognostic landscape of chronic HFrEF, yielding profound clinical implications.

show abstract

“…Correspondingly, in REAL.IT, sacubitril/valsartan significantly improved the peak VO 2 , which, together with a decrease in the VE/VCO 2 slope, indicated an overall improvement in the functional and cardiopulmonary capacities of the patients. Sacubitril/valsartan has also been shown to benefit a 6-min walk distance (25)(26)(27)(35)(36)(37).…”

Section: Discussionmentioning

confidence: 99%

Effects of sacubitril/valsartan on the functional capacity of real-world patients in Italy: the REAL.IT study on heart failure with reduced ejection fraction

Sarullo,

Nugara,

Sarullo

et al. 2024

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

BackgroundHeart failure (HF) significantly affects the morbidity, mortality, and quality of life of patients. New therapeutic strategies aim to improve the functional capacity and quality of life of patients while controlling HF-related risks. Real-world data on both the functional and cardiopulmonary exercise capacities of patients with HF with reduced ejection fraction upon sacubitril/valsartan use are lacking.MethodsA multicenter, retrospective, cohort study, called REAL.IT, was performed based on the data collected from the electronic medical records of nine specialized HF centers in Italy. Cardiopulmonary exercise testing was performed at baseline and after 12 months of sacubitril/valsartan therapy, monitoring carbon dioxide production (VCO2) and oxygen consumption (VO2).ResultsThe functional capacities of 170 patients were evaluated. The most common comorbidities were hypertension and diabetes (i.e., 53.5 and 32.4%, respectively). At follow-up, both the VO2 peak (from 15.1 ± 3.7 ml/kg/min at baseline to 17.6 ± 4.7 ml/kg/min at follow-up, p < 0.0001) and the predicted % VO2 peak (from 55.5 ± 14.1 to 65.5 ± 16.9, p < 0.0001) significantly increased from baseline. The VO2 at the anaerobic threshold (AT-VO2) increased from 11.5 ± 2.6 to 12.5 ± 3.3 ml/kg/min (p = 0.021), and the rate ratio between the oxygen uptake and the change in work (ΔVO2/Δwork slope) improved from 9.1 ± 1.5 to 9.9 ± 1.6 ml/min/W (p < 0.0001).ConclusionsSacubitril/valsartan improves the cardiopulmonary capacity of patients with HFrEF in daily clinical practice in Italy.

show abstract

Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience

Cited by 6 publications

References 35 publications

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population

Effects of sacubitril/valsartan on the functional capacity of real-world patients in Italy: the REAL.IT study on heart failure with reduced ejection fraction

Contact Info

Product

Resources

About